Quick Answer
Lakefront Biotherapeutics NV reported Research And Development Expense of $459.42 million for the year ending 2025.
- Lakefront Biotherapeutics NV showed an increase of +37.0% in Research And Development Expense from 2024 to 2025.
- This data is from Lakefront Biotherapeutics NV's annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Lakefront Biotherapeutics NV's Research And Development Expense has grown by 254.2%.
- Historical annual values: Fiscal year 2025: $459.42 million | Fiscal year 2024: $335.46 million | Fiscal year 2023: $241.29 million | Fiscal year 2022: $269.80 million | Fiscal year 2021: $320.50 million | Fiscal year 2020: $523.67 million | Fiscal year 2019: $420.09 million | Fiscal year 2018: $316.22 million | Fiscal year 2017: $218.50 million | Fiscal year 2016: $139.57 million | Fiscal year 2015: $129.71 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: